EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CytoSorbents's enterprise value is $83.64 Mil.
CytoSorbents's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $35.33 Mil. Therefore, CytoSorbents's EV-to-Revenue for today is 2.37.
The historical rank and industry rank for CytoSorbents's EV-to-Revenue or its related term are showing as below:
CTSO'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3 Med: 8.01 Max: 59.26
Current: 2.37
During the past 13 years, the highest EV-to-Revenue of CytoSorbents was 59.26. The lowest was 1.30. And the median was 8.01.
CTSO's EV-to-Revenue is ranked better than 59.9% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 3.175
vs CTSO: 2.37
As of today (2025-07-05), CytoSorbents's stock price is $1.09.
CytoSorbents's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.63. Therefore, CytoSorbents's PS Ratio for today is 1.72.
CytoSorbents EV-to-Revenue Historical Data
The historical data trend for CytoSorbents's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoSorbents's EV-to-Revenue
For the Medical Devices subindustry, CytoSorbents's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoSorbents's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CytoSorbents's EV-to-Revenue falls into.
CytoSorbents's current Enterprise Value is $83.64 Mil.
CytoSorbents's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents's share price for today is $1.09.
CytoSorbents's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CytoSorbents's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTSO has been successfully added to your 